This video requires your consent.

MOVIVA®

Turn down the food noise

MOVIVA® es la innovadora solución endoscópica mínimamente invasiva para la ablación de la mucosa gástrica (AMG) en el fundus. Reduce la sensación de hambre del paciente y, cuando se combina con la gastroplastia endoscópica (ESG), la AMG puede producir resultados de pérdida de peso comparables a los de la cirugía bariátrica tradicional.

“Minimally invasive endoscopic techniques that target appetite regulation through precise ablation of the gastric fundus offer patients an effective pathway to weight loss without the risks associated with surgery. MOVIVA®’s innovative injection and ablation capabilities simplify the GMA procedure and could set a new standard in endoscopic bariatric care.”

Prof. Ivo Boskoski
Prof. Ivo Boskoski

Rome, Italy

“Combining GMA with ESG represents one of the most promising breakthroughs in non-surgical weight loss treatment. In our early clinical trials, this dual approach achieved total body weight loss of 23 to 24 percent - comparable to surgical sleeve gastrectomy, but without the need for surgery. Patients consistently report greater control over hunger, reduced cravings, and an improved relationship with food. These results are not just clinically significant - they are potentially life-changing.”

Christopher McGowan
Christopher McGowan

MD, Charlotte, U.S.

AMG: cómo funciona

El procedimiento AMG consiste en la ablación de la mucosa del fondo gástrico. Esto reduce la producción de grelina, la llamada hormona del hambre, lo que se traduce en menos hambre y menos antojos. Al mismo tiempo, la ablación del tejido provoca una reducción del fondo gástrico.

This video requires your consent.

This video requires your consent.

Procedimiento AMG con MOVIVA®

Ablación endoscópica del fondo gástrico con MOVIVA®: En primer lugar, se marca el borde distal del fondo con puntos mediante activaciones cortas de APC.

La zona que se va a ablacionar se eleva con solución salina mediante una inyección sin aguja a alta presión y, a continuación, se ablaciona con coagulación por plasma de argón (APC). Estos dos pasos se repiten hasta que se ha ablacionado toda la zona.

Cuando la AMG se combina con la ESG, el enfoque logra resultados de pérdida de peso comparables a los de la gastrectomía vertical en manga (VSG), pero es menos invasivo.

DESCARGUE NUESTRO FOLLETO ELECTRÓNICO

Una nueva incorporación a su cartera de tratamientos

MOVIVA® ofrece una alternativa viable para los pacientes que temen los efectos secundarios y los riesgos de las intervenciones quirúrgicas bariátricas.

Comience hoy mismo su andadura clínica con MOVIVA®

Para garantizar resultados fiables durante la AMG con MOVIVA®, ofrecemos cursos de formación específicos. 
Estos cursos están disponibles en varios países y regiones.

¡Reserve su curso ahora!

Información científica

Publication
Gadi SR, et al. (2026) “Gastric fundal mucosal ablation followed by endoscopic sleeve gastroplasty in adults with obesity: a first-in-human two-phase pilot clinical trial.” Endoscopy, 2026. 

Objective
Endoscopic sleeve gastroplasty (ESG) achieves moderate weight loss but is less effective than surgical vertical sleeve gastrectomy, partly due to preservation of the gastric fundus. Gastric fundal mucosal ablation (GFMA) has been shown to reduce ghrelin levels and appetite.
This study aimed to evaluate the effectiveness and safety of sequential GFMA followed by ESG in adults with obesity, with the hypothesis that the combined approach may improve weight loss outcomes.

Conclusion
Sequential GFMA followed by ESG is safe, feasible, and highly effective, resulting in substantial and clinically meaningful weight loss. The combined approach targets both hormonal (ghrelin) and mechanical/visceroceptive pathways of appetite regulation, potentially overcoming limitations of ESG alone. This strategy represents a promising advancement in endoscopic obesity treatment, though larger and long-term studies are required for validation

More information

Publication
Boškoski Ivo et al. (2026). “Combined gastric mucosal ablation of the fundus using a new hybrid device with endoscopic sleeve gastroplasty for obesity.” Endoscopy 2026; 58: E141–E142 

Objective
The case report describes a novel combined endoscopic approach for obesity treatment that integrates endoscopic sleeve gastroplasty (ESG) with gastric mucosal ablation (GMA) of the fundus, aiming to enhance weight loss through both mechanical restriction and hormonal modulation. 

Conclusion
The combined ESG + GMA approach demonstrates feasibility and safety and shows promising short-term weight loss outcomes. However, larger studies are required to confirm its long-term efficacy and safety.

 

More information

Publication
McGowan, C. E., et al. (2025). “Combination gastric fundus mucosal ablation and endoscopic sleeve gastroplasty: Results from two first-inhuman studies.” Gastrointestinal Endoscopy, Volume 101, Issue 5, S58.

Objective
To evaluate the safety and efficacy of combining Gastric Fundus Mucosal Ablation (GFMA) with Endoscopic Sleeve Gastroplasty (ESG) as a non-surgical outpatient procedure for weight loss in adults with obesity.

Conclusion
The integration of GFMA with ESG offers a promising, minimally invasive alternative to surgical weight loss procedures, delivering comparable efficacy with a favorable safety profile.

 

More information

Publication

De Siena et al. (2025). “A pilot study to evaluate the efficacy and safety of Gastric Mucosal Ablation (GMA) of the fundus with Hybrid Argon Plasma Coagulation (HybridAPC) combined with Endoscopic Sleeve Gastroplasty (ESG) in obese patients” ESGE Days 2025

More information

Publication

Maselli, Daniel B et al. (2024) “Endoscopic Gastric Fundal Mucosal Ablation Induces Weight Loss in Adults With Obesity.” Gastroenterology vol. 167,7 (2024): 1457-1459.e3.

More information

MOVIVA®: tecnología híbrida para AMG

MOVIVA® es un instrumento híbrido avanzado diseñado para la AMG. Combina dos funciones clave en un solo producto:

  1. Inyección de líquido para formar un cojín submucoso que protege las capas de tejido más profundas de lesiones térmicas
  2. Ablación térmica superficial de la mucosa mediante APC.
    MOVIVA® está equipado con el modo moveAPD® específico, que proporciona una APC amplia y consistente.

¡Manténgase al día!

¿Tiene alguna pregunta?

¿Tiene alguna pregunta sobre MOVIVA® o AMG?
Póngase en contacto con nosotros, ¡estaremos encantados de ayudarle!

Contáctenos us